サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1538169

X染色体連鎖性低リン血症市場レポート：2030年までの動向、予測、競合分析

X-Linked Hypophosphatemia Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日
発行
Lucintel
ページ情報
英文 150 Pages
納期
3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

X染色体連鎖性低リン血症市場レポート：2030年までの動向、予測、競合分析
出版日: 2024年07月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

X染色体連鎖性低リン血症の動向と予測

世界のX染色体連鎖性低リン血症市場は、2024年から2030年にかけてCAGR 9.5％で成長すると予測されます。この市場の主な促進要因は、XLH症例の増加と遺伝性疾患の研究開発への投資の増加です。世界のX染色体連鎖性低リン血症市場の将来は、病院・クリニック市場および研究センター市場における機会によって有望視されています。

セグメント別のX染色体連鎖性低リン血症

本調査には、世界のX染色体連鎖性低リン血症の治療、最終用途、地域別の予測が含まれています。

X染色体連鎖性低リン血症市場の洞察

Lucintel社の予測によると、予測期間中、薬剤がより高い成長を遂げる見込みです。

この市場の中では、予測期間中、研究センターがより大きなセグメントであり続けると思われます。

北米は予測期間中最大の地域であり続けるでしょう。

よくある質問

Q1.市場の成長予測は：

A1.世界のX染色体連鎖性低リン血症市場は、2024年から2030年にかけてCAGR 9.5％で成長すると予測されています。

Q2.市場の成長に影響を与える主な促進要因は：

A2.この市場の主な促進要因は、XLH症例数の増加と遺伝性疾患研究開発への投資の増加です。

Q3.市場の主要セグメントは：

A3.X染色体連鎖性低リン血症市場の将来は、病院・クリニック市場および研究センター市場における機会により有望です。

Q4.市場の主要企業は：

A4.主なX染色体連鎖性低リン血症企業は以下の通り：

  • Ultragenyx Pharmaceutical
  • Validus Pharmaceuticals
  • ProSpec-Tany Technogene
  • Merck
  • Zeria Pharmaceutical
  • Smith & Nephew
  • Narang Medical

Q5.今後、最大となる市場セグメントは：

A5.Lucintel社は、薬剤が予測期間中に高い成長を遂げると予測しています。

Q6.市場において、今後5年間に最大になると予想される地域は：

A6.予測期間中、北米が最大の地域であり続けると予想されます。

Q7.レポートのカスタマイズは可能か：

A7.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界のX染色体連鎖性低リン血症市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界のX染色体連鎖性低リン血症市場の動向（2018～2023年）と予測（2024～2030年）
  • 治療別のX染色体連鎖性低リン血症の世界市場
    • 薬剤
    • 外科的/整形外科的治療
  • 最終用途別のX染色体連鎖性低リン血症の世界市場
    • 病院・クリニック
    • 研究センター
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別のX染色体連鎖性低リン血症の世界市場
  • 北米のX染色体連鎖性低リン血症市場
  • 欧州のX染色体連鎖性低リン血症市場
  • アジア太平洋地域のX染色体連鎖性低リン血症市場
  • その他地域のX染色体連鎖性低リン血症市場

第5章 競合分析

  • 製品ポートフォリオ分析
  • 業務統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
  • 世界のX染色体連鎖性低リン血症市場の新たな動向
  • 戦略分析
    • 新製品開発
    • 世界のX染色体連鎖性低リン血症市場の能力拡大
    • 世界のX染色体連鎖性低リン血症市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 主要企業の企業プロファイル

  • Ultragenyx Pharmaceutical
  • Validus Pharmaceuticals
  • ProSpec-Tany Technogene
  • Merck
  • Zeria Pharmaceutical
  • Smith & Nephew
  • Narang Medical
目次

X-Linked Hypophosphatemia Trends and Forecast

The future of the global x-linked hypophosphatemia market looks promising with opportunities in the hospital & clinic and research center markets. The global x-linked hypophosphatemia market is expected to grow with a CAGR of 9.5% from 2024 to 2030. The major drivers for this market are growing numbers of XLH cases and increasing investment in genetic disease research & development.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

X-Linked Hypophosphatemia by Segment

The study includes a forecast for the global x-linked hypophosphatemia by treatment, end use, and region.

X-Linked Hypophosphatemia Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Medication
  • Surgical/Orthopedic Treatment

X-Linked Hypophosphatemia Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals & Clinics
  • Research Centers
  • Others

X-Linked Hypophosphatemia Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of X-Linked Hypophosphatemia Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies x-linked hypophosphatemia companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the x-linked hypophosphatemia companies profiled in this report include-

  • Ultragenyx Pharmaceutical
  • Validus Pharmaceuticals
  • ProSpec-Tany Technogene
  • Merck
  • Zeria Pharmaceutical
  • Smith & Nephew
  • Narang Medical

X-Linked Hypophosphatemia Market Insights

Lucintel forecasts that medication is expected to witness higher growth over the forecast period.

Within this market, research center will remain larger segment over the forecast period.

North America will remain the largest region over the forecast period.

Features of the Global X-Linked Hypophosphatemia Market

Market Size Estimates: X-linked hypophosphatemia market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: X-linked hypophosphatemia market size by treatment, end use, and region in terms of value ($B).

Regional Analysis: X-linked hypophosphatemia market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatments, end uses, and regions for the x-linked hypophosphatemia market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the x-linked hypophosphatemia market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for x-linked hypophosphatemia market?

Answer: The global x-linked hypophosphatemia market is expected to grow with a CAGR of 9.5% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the x-linked hypophosphatemia market?

Answer: The major drivers for this market are growing numbers of XLH cases and increasing investment in genetic disease research & development.

Q3. What are the major segments for x-linked hypophosphatemia market?

Answer: The future of the x-linked hypophosphatemia market looks promising with opportunities in the hospital & clinic and research center markets.

Q4. Who are the key x-linked hypophosphatemia market companies?

Answer: Some of the key x-linked hypophosphatemia companies are as follows:

  • Ultragenyx Pharmaceutical
  • Validus Pharmaceuticals
  • ProSpec-Tany Technogene
  • Merck
  • Zeria Pharmaceutical
  • Smith & Nephew
  • Narang Medical

Q5. Which x-linked hypophosphatemia market segment will be the largest in future?

Answer: Lucintel forecasts that medication is expected to witness higher growth over the forecast period.

Q6. In x-linked hypophosphatemia market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the x-linked hypophosphatemia market by treatment (medication and surgical/orthopedic treatment), end use (hospitals & clinics, research centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global X-Linked Hypophosphatemia Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global X-Linked Hypophosphatemia Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global X-Linked Hypophosphatemia Market by Treatment
    • 3.3.1: Medication
    • 3.3.2: Surgical/Orthopedic Treatment
  • 3.4: Global X-Linked Hypophosphatemia Market by End Use
    • 3.4.1: Hospitals & Clinics
    • 3.4.2: Research Centers
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global X-Linked Hypophosphatemia Market by Region
  • 4.2: North American X-Linked Hypophosphatemia Market
    • 4.2.1: North American X-Linked Hypophosphatemia Market by Treatment: Medication and Surgical/Orthopedic Treatment
    • 4.2.2: North American X-Linked Hypophosphatemia Market by End Use: Hospitals & Clinics, Research Centers, and Others
  • 4.3: European X-Linked Hypophosphatemia Market
    • 4.3.1: European X-Linked Hypophosphatemia Market by Treatment: Medication and Surgical/Orthopedic Treatment
    • 4.3.2: European X-Linked Hypophosphatemia Market by End Use: Hospitals & Clinics, Research Centers, and Others
  • 4.4: APAC X-Linked Hypophosphatemia Market
    • 4.4.1: APAC X-Linked Hypophosphatemia Market by Treatment: Medication and Surgical/Orthopedic Treatment
    • 4.4.2: APAC X-Linked Hypophosphatemia Market by End Use: Hospitals & Clinics, Research Centers, and Others
  • 4.5: ROW X-Linked Hypophosphatemia Market
    • 4.5.1: ROW X-Linked Hypophosphatemia Market by Treatment: Medication and Surgical/Orthopedic Treatment
    • 4.5.2: ROW X-Linked Hypophosphatemia Market by End Use: Hospitals & Clinics, Research Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global X-Linked Hypophosphatemia Market by Treatment
    • 6.1.2: Growth Opportunities for the Global X-Linked Hypophosphatemia Market by End Use
    • 6.1.3: Growth Opportunities for the Global X-Linked Hypophosphatemia Market by Region
  • 6.2: Emerging Trends in the Global X-Linked Hypophosphatemia Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global X-Linked Hypophosphatemia Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global X-Linked Hypophosphatemia Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Ultragenyx Pharmaceutical
  • 7.2: Validus Pharmaceuticals
  • 7.3: ProSpec-Tany Technogene
  • 7.4: Merck
  • 7.5: Zeria Pharmaceutical
  • 7.6: Smith & Nephew
  • 7.7: Narang Medical